Frequently Asked Questions
Factors such as higher demands of oral gels and liquids and increasing incidence in elderly population are the major drivers for the global sialorrhea market.
Pfizer Inc (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Mylan N.V. (U.S.), Fresenius Kabi AG (Germany), Hikma Pharmaceuticals PLC (U.K.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd. (Israel), Bristol Myers Squibb Company (U.S.) GSK Plc. (U.K), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd (India), Merz Pharma (Germany), USWM, LLC. (U.S.).
North America dominates the market due to increased public-private partnerships to promote R&D activities for the treatment of sialorrhea in the region.
Asia-Pacific has been witnessing positive growth for the global sialorrhea market throughout the forecasted period due to advanced healthcare facilities and the presence of multiple treatment options.